ES2381452T3 - PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas - Google Patents
PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas Download PDFInfo
- Publication number
- ES2381452T3 ES2381452T3 ES08839793T ES08839793T ES2381452T3 ES 2381452 T3 ES2381452 T3 ES 2381452T3 ES 08839793 T ES08839793 T ES 08839793T ES 08839793 T ES08839793 T ES 08839793T ES 2381452 T3 ES2381452 T3 ES 2381452T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- alkylene
- aryl
- group
- het
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de fórmula 1, R3 en la cual X es SO o SO2; R1 es H, alquilo C1-6, R2 es H o un radical seleccionado del grupo consistente en alquilo C1-10 y alquenilo C2-6, que eventualmente puede estar sustituido con uno o varios radicales seleccionados de halógeno y fluoroalquilo C1-3 o que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo que consiste en OROR2.1 SR2.1 SO2-R2.1, COOR2.1 , CONR2.2R2.3 , , SO-R2.1 , , arilo C6-10, -Het, Hetarilo, un cicloalquilo C3-10 monocíclico o bicíclico, CH2-NR2.2R2.3 y NR2.2R2.3 , que, de nuevo, puede estar eventualmente sustitudo con uno o varios radicales seleccionados del grupo consistente en OH, halógeno, OR2.1, oxo, CF3, CHF2, CH2F, alquilo C1-6, alcanol C1-6, arilo C6-10, COOR2.1 , CH2-NR2.2R2.3 y NR2.2R2.3 , en donde Het es un heterociclo de uno a once miembros, mono-o bi-cíclico, saturado o parcialmente saturado, eventualmente condensado o eventualmente puenteado, que contiene 1, 2, 3 ó 4 heteroátomos elegidos, independientemente uno de otro, del grupo consistente en N, S u O, y en donde Hetarilo es un heteroarilo de cinco a diez miembros, mono-o bi-cíclico, eventualmente condensado, que contiene 1, 2, 3 ó 4 heteroátomos seleccionados, independientemente uno de otro, del grupo consistente en N, S u O, y en donde cicloalquilo puede estar saturado o parcialmente saturado, en donde R2.1 es H o un radical seleccionado del grupo consistente en alquilo C1-6-, alcanol C1-6, haloalquilo C1-3, cicloalquilo C3-10 mono-o bi-cíclico, aril C6-10-alquileno C1-6, hetaril-alquileno C1-6, Het-alquileno C1-6, cicloalquil C3-10-alquileno C1-6, un arilo C6-10 mono-o bi-cíclico, heteroarilo y un -Het, que eventualmente puede estar sustituido con uno varios radicales seleccionados del grupo consistente en OH, O- (alquilo C1-3) , halógeno, alquilo C1-6 y arilo C6-10, y R2.3 en donde R2.2 son, de modo independiente entre sí, H o un radical que está seleccionado del grupo compuesto por alquilo C1-6, cicloalquilo C3-10 mono-o bicíclico, aril C6-10-alquileno C1-6, hetarilalquileno C1-6, arilo C6-10 mono-o bicíclico, Het, Hetarilo, CO-NH2, CO-NHCH3, CO-N (CH3) 2, SO2 (alquilo C1-C2) , CO-R2.1 y COOR2.1 , que eventualmente puede estar sustituido con uno o más radicales seleccionados del grupo consistente en OH, halógeno, alquilo C1-6, arilo C6-10 y COOR2.1 , o R2 es un cicloalquilo C3-10 mono-o policíclico que eventualmente puede estar puenteado una o varias veces a través de grupos alquilo C1-3 y que eventualmente puede estar sustituido con un radical seleccionado del grupo compuesto por alcanol C1-6 ramificado o no ramificado, fluoroalquilo C1-3, alquilen C1-3-OR2.1, OR2.1 , COOR2.1 , - SO2-NR2.2R2.3, Het, -NH-CO-O- (alquilo C1-6) , -NH-CO- (alquilo C1-6) , -NH-CO-O- (arilo C6-10) , -NH-CO- (arilo C6-10) , -NH-CO-O-Hetarilo, -NH-CO-Hetarilo, -NH-CO-O- (alquilen C1-3) - (arilo C6-10) , -NH-CO- (alquilen C1-3) (arilo C6-10) , -N (alquil C1-3) -CO- (alquilo C1-6) , -N (alquil C1-3) -CO-O- (arilo C6-10) , -N (alquil C1-3) -CO- (arilo C6-10) , - N (alquil C1-3) -CO-O-Hetarilo, -N (alquil C1-3) -CO-hetarilo, -N (alquil C1-3) -CO-O- (alquilen C1-3) - (arilo C6-10) , N (alquil C1-3) -CO- (alquilen C1-3) - (arilo C6-10) , arilo C6-10, alquilo C1-6, aril C6-10-alquileno C1-6, Hetaril-alquileno C1-6, cicloalquilo C3-10 mono-o bi-cíclcico y NR2.2R2.3 , que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo compuesto por OH, OR2.1, oxo, halógeno, CF3, CHF2, CH2F, alquilo C1-6, arilo C6-10 y NR2.2R2.3 , o R2 es un arilo C6-10 mono-o poli-cíclico, que eventualmente puede estar sustituido con OH, SH o halógeno o OR2.1 NR2.2R2.3 con uno o varios radicales seleccionados del grupo consistente en , COOR2.1 , , CH2NR2.2R2.3, cicloalquilo C3-10, Het, alquilo C1-6, fluoroalquilo C1-3, CF3, CHF2, CH2F, aril C6-10-alquileno C1-6, Het-alquileno C1-6, Hetaril-alquileno C1-6, arilo C6-10, SO2-CH3, SO2-CH2CH3 y SO2-NR2.2R2.3 , que, de nuevo, puede estar eventualmente sustituido con uno o varios radicales seleccionados del grupo consistente en OH, OR2.1, CF3, CHF2, CH2F, oxo, halógeno, CF3, CHF2, CH2F, alquilo C1-6, arilo C6-10 y NR2.2R2.3 , o R2 es un radical seleccionado de un grupo consistente en Het y Hetarilo, que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo halógeno, OH, oxo, CF3, CHF2 y CH2F o con uno o varios radicales seleccionados del grupo OR2.1, alquilen C1-3-OR2.1, SR2.1, SO-R2.1, SO2-R2.1, COOR2.1 , COR2.1, alcanol C1-6, cicloalqulo C3-10 mono-o bi-cíclico, arilo C6-10, alquilo C1-6, aril C6-10-alquileno C1-6, hetaril-alquileno C1-6, Het, Hetarilo, alquilen C1-3-OR2.1 y NR2.2R2.3 , que, de nuevo, eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo compuesto por OH, OR 2.1, oxo, halógeno, CF3, CHF2, CH2F, alquilo C1-6, arilo C6-10 y NR2.2R2.3 , o en donde NR1R2 son juntos un anillo heterocíclico C4-7 que eventualmente puede estar puentado, que contiene 1, 2 ó 3 heteroátomos seleccionados del grupo consistente en N, O y S y que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo consistente en OH, OR2.1, alquilen C1-3-OR.1 , oxo, halógeno, alquilo C1-6, arilo C6-10, COOR2.1, CH2-NR2.2-COO-R2.1, CH2-NR2.2-CO-R2.1, CH2-NR2.2-CO-CH2 NR2.2R2.3 CH2-NR2.2-SO2-NR2.2R2.3 , CH2-NR2.2-SO2-alquilo C1-3, , CH2-NR2.2-CO-NR2.2R2.3 , CO-NR2.2R2.3 , CH2-NR2.2R2.3 y NR2.2R2.3 , y en donde R3 es un arilo C6-10, que, eventualmente, puede estar sustituido en posición orto, para o meta con uno, dos o tres radicales seleccionados, independientemente uno de otro, del grupo consistente en flúor, cloro, bromo, hidroxi, CN, alquilo C1-6, fluoroalquilo C1-3, -alquilen C1-3-OR2.1, -alquilen C1-3-NR2.2R2.3, -NR2.2R2.3, O-R2.1; SO-R2.1, SO2R2.1, COOR2.1 , -CO-NH- (alquilen C1-6) -Hetarilo, -CO-NH-Hetarilo, -CO-N (CH3) -Het, -CO-N (CH3) - (alquilen C1-3) -Het, -CO-N (CH3) - (alquilen C1-3) -Hetarilo, -CO-N (cicloalquil C3-7) -Het, -CO-NR2.2R2.3 , -CO-NH (alquilen C1-6) -Het, NR2.2-CO-R2.1, arilo C6-10, aril C6-10-alquileno C1-2, Het-alquileno C1-2, -Het, -CO-Het, CO-N (CH3) -cicloalquilo C3-7, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-2, Hetaril-alquileno C1-2 y Hetarilo, en donde este radical puede estar eventualmente sustituido con uno o varios radicales seleccionados del grupo consistente en OH, halógeno, -fluoroalquilo C1-3, oxo, metilo y fenilo, o en donde R3 es un radical seleccionado del grupo consistente en Het y Hetarilo, que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo consistente en halógeno, fluoroalquilo C1-3, CN, OH, oxo, -alquilo C1-6, -alquilen C1-3-NR2.2R2.3 , -NR2.2R2.3, SO-R2.1, SO2-R2.1, -O-R2.1 , -COOR2.1, SO2 (CH3) , SO2- (CH2-CH3) , arilo C6-10, Het, cicloalquilo C3-7 y Hetarilo, que, de nuevo, eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo consistente en OH, halógeno, -fluoroalquilo C1-3, alquilo C1-6, arilo C6-10, -COO (alquilo C1-3) y O- (alquilo C1-3) , o en donde R3 es -O-R3.1 , en donde R3.1 es un radical seleccionado del grupo consistente en -alquilo C1-6, -arilo C6-10, -alquilen C1-3-arilo C6-10, Hetarilo y Het, que, eventualmente puede estar sustituido, en posición orto, para o meta, con uno, dos o tres radicales seleccionados, independientemente uno de otro, del grupo consistente en flúor, cloro, bromo, hidroxi, CN, alquilo C1-6, fluoroalquilo C1-3, CO- (alquilo C1-5) , -CO- (fluoroalquilo C1-3) , -CONH- (alquilen C1-6) -Hetarilo, -CO-N (alquil C1-3) - (alquilen C1-6) -Hetarilo, -CO-N (alquil C1-3) -Het, -CO-N (cicloalquil C3-7) -Het, -alquilen C1-3-OR2.1 , -alquilen C1-3-NR2.2R2.3, -NR2.2R2.3, O-R2.1; SO-R2.1, SO2-R2.1, COOH, COO- (alquilo C1-4) , -O-alquilen C1-3-N (alquilo C1-3) 2, CO-NR2.2R2.3, NR2.2-CO-R2.1 , arilo C6-10, aril C6-10-alquileno C1-2, Het-alquileno C1-2, -CO-Het, Het, -CO-cicloalquilo C3-7, -CO-N (alquil C1-3) -cicloalquilo C3-7, ciloalquilo C3-7, ciloalquil C3-7-alquileno C1-2, Hetaril-alquileno C1-2 y Hetarilo, que, de nuevo, eventualmente puede estar sustituido con 1, 2, 3 ó 4 radicales seleccionados, independientemente uno de otro, del grupo consistente en F, Cl, Br, metilo, O-metilo, etilo, O-etilo, OH, oxo y CF3. y en donde R4 es H, CN, OH, CF3, CHF2, CH2F, F, metilo, etilo, -O- (alquilo C1-3) , -alquilen C1-3-OH, -COO (alquilo C1-3) , -CO-Het, - (alquilen C1-2) -NH-SO2- (alquilo C1-2) , - (alquilen C1-2) -N (alquil C1-3) -SO2- (alquilo C1-2) , - (alquilen C1-2) -O- (alquilen C1-2) -arilo C6-10, -alquilen C1-3-O-alquilo C1-3, - (alquilen C1-2) -N (alquil C1-3) -CO- (alquilo C1-2) , -NH-CO- (alquilen C1-3) -O- (alquilo C1-3) , -alquilen C1-3-NH-CO- (alquilo C1-3) , -alquilen C1-3-NH-CO- (alquilen C1-3) -N (alquilo C1-3) 2, -O- (alquilen C1-2) - (arilo C6-10) , -alquilen C1-3-NH-CO- (alquilen C1-3) -O- (alquilo C1-3) , -CO- (arilo C6-10) , - (alquilen C1-2) -N (alquil C1-3) -CO- (alquilen C1-2) -O- (alquilo C1-3) , en donde el arilo en los radicales anteriores puede estar sustituido, eventualmente de nuevo, con uno o varios otros radicales seleccionados del grupo F, Cl, Br, metilo, etilo, propilo, isopropilo, ciclopropilo, -Ometilo, -O-etilo, -O-propilo, -O-isopropilo, -O-ciclopropilo, -OH y CF3 , o en donde R3 y R4 , en común, forman un heterociclo mono-o bi-cíclico insaturado, saturado o parcialmente saturado, que contiene 1, 2 ó 3 heteroátomos seleccionados del grupo consistente en N, O y S y que, eventualmente, puede estar sustituido con uno o varios radicales seleccionados del grupo consistente en halógeno, OH, oxo, fluoroalquilo C1-3, CN, alquilo C1-6, -O-R2.1 , -COOR2.1, SO-R2.1, SO2-R2.1, -alquilen C1-3-NR2.2R2.3 , NR2.2R2.3, arilo C6-10, cicloalquilo C3-7, Het y Hetarilo, así como sales farmacológicamente compatibles de los mismos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07118901 | 2007-10-19 | ||
EP07118901 | 2007-10-19 | ||
PCT/EP2008/063999 WO2009050248A1 (de) | 2007-10-19 | 2008-10-16 | Substituierte piperidino-dihydrothienopyrimidine |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2381452T3 true ES2381452T3 (es) | 2012-05-28 |
Family
ID=39154006
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13154790.3T Active ES2524910T3 (es) | 2007-10-19 | 2008-10-16 | Piperidino-dihidrotienopirimidinas sustituidas |
ES08839793T Active ES2381452T3 (es) | 2007-10-19 | 2008-10-16 | PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13154790.3T Active ES2524910T3 (es) | 2007-10-19 | 2008-10-16 | Piperidino-dihidrotienopirimidinas sustituidas |
Country Status (34)
Country | Link |
---|---|
US (1) | US8754073B2 (es) |
EP (3) | EP2610258B1 (es) |
JP (2) | JP5150728B2 (es) |
KR (1) | KR101548975B1 (es) |
CN (2) | CN104069112A (es) |
AR (1) | AR069075A1 (es) |
AT (1) | ATE542825T1 (es) |
AU (1) | AU2008313660B2 (es) |
BR (1) | BRPI0818006B8 (es) |
CA (1) | CA2705414C (es) |
CL (1) | CL2008003096A1 (es) |
CY (2) | CY1112703T1 (es) |
DK (2) | DK2610258T3 (es) |
EA (1) | EA019480B1 (es) |
EC (1) | ECSP10010156A (es) |
ES (2) | ES2524910T3 (es) |
HK (1) | HK1145677A1 (es) |
HR (2) | HRP20120334T1 (es) |
MA (1) | MA31845B1 (es) |
ME (1) | ME01330B (es) |
MX (1) | MX2010004026A (es) |
MY (1) | MY153979A (es) |
NZ (1) | NZ585346A (es) |
PE (2) | PE20091386A1 (es) |
PL (2) | PL2215092T3 (es) |
PT (2) | PT2610258E (es) |
RS (1) | RS52271B (es) |
SI (2) | SI2215092T1 (es) |
TN (1) | TN2010000175A1 (es) |
TW (1) | TWI421077B (es) |
UA (1) | UA99309C2 (es) |
UY (1) | UY31405A1 (es) |
WO (1) | WO2009050248A1 (es) |
ZA (1) | ZA201001683B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
US8653282B2 (en) | 2007-10-18 | 2014-02-18 | Boehringer Ingelheim International Gmbh | Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein |
CA2705414C (en) * | 2007-10-19 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Substituted piperidino-dihydrothienopyrimidines |
WO2009050236A1 (de) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Neue piperazino-dihydrothienopyrimidin-derivate |
CN101827853A (zh) | 2007-10-19 | 2010-09-08 | 贝林格尔.英格海姆国际有限公司 | 杂环取代的哌嗪子基-二氢噻吩并嘧啶 |
CA2753604A1 (en) * | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Drug combinations containing pde4-inhibitors and nsaids |
WO2011124524A1 (de) | 2010-04-08 | 2011-10-13 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten |
EP2555774B1 (de) | 2010-04-08 | 2015-10-21 | Boehringer Ingelheim International GmbH | Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten |
US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
US9013997B2 (en) * | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
US9499519B2 (en) | 2012-12-26 | 2016-11-22 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
WO2014117948A1 (en) * | 2013-02-04 | 2014-08-07 | Grünenthal GmbH | Novel substituted condensed pyrimidine compounds |
WO2014124860A1 (en) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Specific pde4b-inhibitors for the treatment of diabetes mellitus |
HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
CN104892720B (zh) * | 2014-03-07 | 2016-10-26 | 华东师范大学 | 4,4-二甲基石胆酸-2,3-骈n-芳基吡唑衍生物及其制备方法和应用 |
WO2018003962A1 (ja) * | 2016-06-30 | 2018-01-04 | 国立研究開発法人理化学研究所 | 新規化合物又はその薬理学的に許容される塩 |
CN111108109A (zh) | 2017-09-20 | 2020-05-05 | 利奥制药有限公司 | 取代的二氢噻吩并嘧啶及其作为磷酸二酯酶抑制剂的用途 |
EA202090977A1 (ru) | 2017-10-23 | 2020-09-04 | Бёрингер Ингельхайм Интернациональ Гмбх | Новая комбинация активных агентов для лечения прогрессирующих фиброзирующих интерстициальных заболеваний легких (pf-ild) |
ES2935615T3 (es) | 2017-12-15 | 2023-03-08 | Union Therapeutics As | Azetidina dihidrotienopiridinas sustituidas y su uso como inhibidores de la fosfodiesterasa |
WO2019115774A1 (en) | 2017-12-15 | 2019-06-20 | Leo Pharma A/S | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors |
WO2019115775A1 (en) | 2017-12-15 | 2019-06-20 | Leo Pharma A/S | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors |
WO2020048827A1 (en) * | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
US20230190754A1 (en) | 2021-12-09 | 2023-06-22 | Boehringer Ingelheim International Gmbh | Therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases |
TW202339731A (zh) | 2021-12-09 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法 |
WO2023232135A1 (zh) * | 2022-06-02 | 2023-12-07 | 西藏海思科制药有限公司 | Pde4b抑制剂及其用途 |
CN117247395A (zh) * | 2022-06-16 | 2023-12-19 | 武汉人福创新药物研发中心有限公司 | Pde4b抑制剂 |
CN115040503B (zh) * | 2022-07-26 | 2023-10-10 | 云南民族大学 | 螺环二烯酮型木脂素类化合物在制药中的应用 |
WO2024032673A1 (zh) * | 2022-08-09 | 2024-02-15 | 西藏海思科制药有限公司 | Pde4b抑制剂及其用途 |
WO2024068386A1 (en) | 2022-09-28 | 2024-04-04 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor |
WO2024067660A1 (zh) * | 2022-09-29 | 2024-04-04 | 苏州爱科百发生物医药技术有限公司 | 氮杂稠环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1470336A1 (de) | 1962-07-04 | 1969-03-20 | Thomae Gmbh Dr K | Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung |
NL124131C (es) | 1963-06-17 | |||
DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
BE663693A (es) | 1965-03-31 | |||
DE2032687A1 (en) | 1970-07-02 | 1972-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa |
BE754606A (fr) * | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
DE1940572A1 (de) | 1969-08-08 | 1971-02-11 | Thomae Gmbh Dr K | Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
US3763156A (en) * | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
FR2082496A5 (es) | 1970-03-18 | 1971-12-10 | Westinghouse Freins & Signaux | |
DE2121950A1 (en) | 1971-05-04 | 1972-11-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity |
DE2750288A1 (de) * | 1977-11-10 | 1979-05-17 | Thomae Gmbh Dr K | Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
US4256737A (en) * | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
US5187168A (en) * | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
US5491201A (en) | 1992-02-06 | 1996-02-13 | The Dow Chemical Company | Mesogenic cyclic imino ether-containing compositions and polymerization products thereof |
JPH07330777A (ja) | 1994-06-08 | 1995-12-19 | Taisho Pharmaceut Co Ltd | チエノ[3,2−d]ピリミジン−4−オン誘導体 |
JPH09301958A (ja) | 1996-05-09 | 1997-11-25 | Nippon Shoji Kk | 新規ピリミジン化合物及び抗ロタウイルス剤 |
US6339089B2 (en) | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
JP2003520042A (ja) | 2000-01-24 | 2003-07-02 | アイシス・ファーマシューティカルス・インコーポレーテッド | 誘導性一酸化窒素シンターゼ発現のアンチセンスモジュレーション |
GB0004153D0 (en) | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
OA12403A (en) | 2000-10-12 | 2006-04-18 | Boehringer Ingelheim Pharma | Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament. |
DE10064994A1 (de) | 2000-12-23 | 2002-07-04 | Merck Patent Gmbh | Sulfamidothienopyrimidine |
CN100343258C (zh) | 2001-04-30 | 2007-10-17 | 美国拜尔公司 | 新的4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物 |
AR035700A1 (es) | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
BR0210537A (pt) | 2001-06-22 | 2004-06-22 | Boehringer Ingelheim Pharma | Anticolinérgico cristalino, processo para a sua preparação e sua aplicação para a preparação de um medicamento |
US6587548B2 (en) * | 2001-07-17 | 2003-07-01 | Hewlett-Packard Development Co., L.P. | Method and system of using a single telephone number for multiple services |
AU2002364211A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
AU2003202263A1 (en) | 2002-01-10 | 2003-07-30 | Bayer Healthcare Ag | Roh-kinase inhibitors |
SE0203304D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Coumpounds |
RS20050810A (en) | 2003-04-29 | 2007-08-03 | Pfizer Inc., | 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension |
EP1654385A4 (en) | 2003-05-16 | 2006-11-08 | Wisconsin Alumni Res Found | METHOD FOR ISOLATING AND CLONING HIGH MOLECULAR WEIGHT POLYNUCLEOTIDE MOLECULES FROM THE ENVIRONMENT |
JP2005003345A (ja) | 2003-05-21 | 2005-01-06 | Showa Denko Kk | 換気兼熱交換装置および空調システム |
MX338455B (es) * | 2003-10-02 | 2016-04-18 | Dsm Ip Assets Bv | Produccion de altos niveles de dha en microalgas usando cantidades modificadas de cloruro y potasio. |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
US20050137186A1 (en) | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
ATE457309T1 (de) | 2003-12-23 | 2010-02-15 | Serodus As | Modulatoren von peripheren 5-ht-rezeptoren |
WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
GB0427403D0 (en) | 2004-12-15 | 2005-01-19 | Astrazeneca Ab | Novel compounds I |
DE102005019201A1 (de) | 2006-04-19 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen |
EP1940392A2 (en) | 2005-05-11 | 2008-07-09 | Nycomed GmbH | Combination of the pde4 inhibitor and a tetrahydrobiopterin derivative |
EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
SI2137196T1 (sl) | 2007-04-20 | 2011-01-31 | Glaxo Group Ltd Glaxo Welcome House | Tricikliäśne spojine, ki vsebujejo duĺ ik, uporabne kot antibakterijska sredstva |
US8653282B2 (en) | 2007-10-18 | 2014-02-18 | Boehringer Ingelheim International Gmbh | Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein |
JP2011500621A (ja) * | 2007-10-19 | 2011-01-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規フェニル置換ピペラジノ−ジヒドロチエノピリミジン |
CA2705414C (en) | 2007-10-19 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Substituted piperidino-dihydrothienopyrimidines |
US8796460B2 (en) | 2007-10-19 | 2014-08-05 | Mercky Sharp & Dohme Corp. | Compounds for inhibiting KSP kinesin activity |
KR20100090777A (ko) | 2007-10-19 | 2010-08-17 | 아스트라제네카 아베 | 대사성 글루타메이트 수용체 (mglur)의 조절제로서의 테트라졸 유도체 |
WO2009050236A1 (de) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Neue piperazino-dihydrothienopyrimidin-derivate |
FR2922550B1 (fr) * | 2007-10-19 | 2009-11-27 | Sanofi Aventis | Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet |
CN101827853A (zh) | 2007-10-19 | 2010-09-08 | 贝林格尔.英格海姆国际有限公司 | 杂环取代的哌嗪子基-二氢噻吩并嘧啶 |
CA2753604A1 (en) | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Drug combinations containing pde4-inhibitors and nsaids |
EP2400961B1 (de) | 2009-02-27 | 2017-11-22 | Boehringer Ingelheim International GmbH | Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids |
US20130059866A1 (en) * | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
-
2008
- 2008-10-16 CA CA2705414A patent/CA2705414C/en active Active
- 2008-10-16 SI SI200830579T patent/SI2215092T1/sl unknown
- 2008-10-16 MY MYPI2010001693A patent/MY153979A/en unknown
- 2008-10-16 PT PT131547903T patent/PT2610258E/pt unknown
- 2008-10-16 EP EP13154790.3A patent/EP2610258B1/de active Active
- 2008-10-16 NZ NZ585346A patent/NZ585346A/en unknown
- 2008-10-16 PL PL08839793T patent/PL2215092T3/pl unknown
- 2008-10-16 KR KR1020107010905A patent/KR101548975B1/ko active IP Right Grant
- 2008-10-16 ME MEP-2012-26A patent/ME01330B/me unknown
- 2008-10-16 RS RS20120144A patent/RS52271B/en unknown
- 2008-10-16 CN CN201410312258.5A patent/CN104069112A/zh active Pending
- 2008-10-16 US US12/738,344 patent/US8754073B2/en active Active
- 2008-10-16 AT AT08839793T patent/ATE542825T1/de active
- 2008-10-16 DK DK13154790.3T patent/DK2610258T3/da active
- 2008-10-16 PL PL13154790T patent/PL2610258T3/pl unknown
- 2008-10-16 WO PCT/EP2008/063999 patent/WO2009050248A1/de active Application Filing
- 2008-10-16 ES ES13154790.3T patent/ES2524910T3/es active Active
- 2008-10-16 DK DK08839793.0T patent/DK2215092T3/da active
- 2008-10-16 CN CN200880112254.5A patent/CN101827852B/zh active Active
- 2008-10-16 ES ES08839793T patent/ES2381452T3/es active Active
- 2008-10-16 MX MX2010004026A patent/MX2010004026A/es active IP Right Grant
- 2008-10-16 JP JP2010529389A patent/JP5150728B2/ja active Active
- 2008-10-16 BR BRPI0818006A patent/BRPI0818006B8/pt active IP Right Grant
- 2008-10-16 SI SI200831314T patent/SI2610258T1/sl unknown
- 2008-10-16 EP EP11174754.9A patent/EP2380891B1/de active Active
- 2008-10-16 EA EA201000609A patent/EA019480B1/ru not_active IP Right Cessation
- 2008-10-16 AU AU2008313660A patent/AU2008313660B2/en active Active
- 2008-10-16 PT PT08839793T patent/PT2215092E/pt unknown
- 2008-10-16 UA UAA201005780A patent/UA99309C2/ru unknown
- 2008-10-16 EP EP08839793A patent/EP2215092B1/de active Active
- 2008-10-17 PE PE2008001796A patent/PE20091386A1/es not_active Application Discontinuation
- 2008-10-17 TW TW097139983A patent/TWI421077B/zh active
- 2008-10-17 CL CL2008003096A patent/CL2008003096A1/es unknown
- 2008-10-17 AR ARP080104560A patent/AR069075A1/es active IP Right Grant
- 2008-10-17 PE PE2013001391A patent/PE20131463A1/es not_active Application Discontinuation
- 2008-10-17 UY UY31405A patent/UY31405A1/es not_active Application Discontinuation
-
2010
- 2010-03-09 ZA ZA201001683A patent/ZA201001683B/xx unknown
- 2010-04-16 TN TN2010000175A patent/TN2010000175A1/fr unknown
- 2010-05-05 EC EC2010010156A patent/ECSP10010156A/es unknown
- 2010-05-12 MA MA32832A patent/MA31845B1/fr unknown
- 2010-12-22 HK HK10111978.1A patent/HK1145677A1/xx not_active IP Right Cessation
-
2012
- 2012-04-16 HR HRP20120334AT patent/HRP20120334T1/hr unknown
- 2012-04-23 CY CY20121100378T patent/CY1112703T1/el unknown
- 2012-12-03 JP JP2012264647A patent/JP5615889B2/ja active Active
-
2014
- 2014-11-26 CY CY20141100984T patent/CY1115858T1/el unknown
- 2014-11-26 HR HRP20141153AT patent/HRP20141153T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2381452T3 (es) | PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas | |
AR086522A1 (es) | Inhibidores heterociclicos de autotaxina y usos de los mismos | |
PE20211501A1 (es) | Piridinonas anti-fibroticas | |
AR060266A1 (es) | Tiazolil - dihidro - indazoles | |
AR082891A1 (es) | Di-azetidinil diamidas como inhibidores de monoacilglicerol lipasas | |
AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
ES2722048T3 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
AR088000A1 (es) | Derivados de pirazolquinolinona, su preparacion y su uso terapeutico | |
PE20150350A1 (es) | Acidos 5-aminotetrahidroquinolin-2-carboxilicos novedosos y su uso | |
AR066799A1 (es) | Antagonistas para el receptor ccr2 y sus usos | |
AR094378A1 (es) | Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral | |
AR083876A1 (es) | 5-halogenopirazolcarboxamidas | |
AR070224A1 (es) | Inhibidores de proteina quinasa y uso de los mismos | |
AR050932A1 (es) | Amidas biciclicas como inhibidores de cinasa | |
AR050610A1 (es) | Derivados de dihidropteridinona | |
AR059513A1 (es) | Derivados benzoil - piperidina como moduladores de 5ht/ d3 | |
AR049319A1 (es) | Derivados de 6-heteroarilfenantridinas | |
PE20081844A1 (es) | DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a | |
AR082004A1 (es) | Compuestos de fusion de piridina | |
ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
AR086837A1 (es) | Moduladores heterociclicos de sintesis lipidica | |
AR080955A1 (es) | Aril-/heteroaril-ciclohexenil-tetraazabenzo(e)azulenos | |
AR053303A1 (es) | Derivados de 4-fenil-pirimidina-2-carbonitrilo y su uso en el tratamiento de enfermedades relacionadas con catepsina k y catepsina s | |
AR066154A1 (es) | Derivados de piperidina / piperazina | |
AR077525A1 (es) | 4-aril-butan-1,3-diamidas y composiciones farmaceuticas |